Protease inhibitors in hepatitis C: from chronic disease to cure.

摘要: The recent publication of two controlled trials on boceprevir and three telaprevir heralds a new era for hepatitis C therapy. Bocreprevir are protease inhibitors which act directly the virus to inhibit replication referred as direct acting antiviral agents (DAAâ?Ts). They first 2 such be licensed but it is hoped that many more will soon follow. These very important studies represent major advance in treatment patients with chronic infection. To appreciate their significance aware some clinical features Firstly, exposure leads infection approximately 70% patients. Over time (years or decades) this may lead hepatitis, cirrhosis, liver failure hepatocellular carcinoma. speed progression depends number co-factors. Patients who male, drink alcohol, overweight, diabetic co-infected HIV have rapid cirrhosis8. In contrast young, non-drinking females progress slowly... Many attend drug clinics. This group rarely receive anti-viral therapy represents bulk population at risk complications C. It has been shown centres, linked methadone treatment, effective ensuring compliance. As infrastructure already exists, widening its remit include should cost effective. A large study from United States confirmed possible provide primary care settings, provided there appropriate back-up.